Aclaris Therapeutics, Inc. (ACRS) formed wedge down with $23.53 target or 6.00% below today’s $25.03 share price. Aclaris Therapeutics, Inc. (ACRS) has $771.79 million valuation. The stock increased 1.50% or $0.37 during the last trading session, reaching $25.03. About 352,503 shares traded or 0.20% up from the average. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has risen 25.57% since January 3, 2017 and is uptrending. It has outperformed by 8.87% the S&P500.
Old National Bancorp operates as the holding firm for Old National Bank that provides various financial services to individual and commercial clients in the United States. The company has market cap of $2.36 billion. The firm offers deposit accounts, including noninterest-bearing demand, negotiable order of withdrawal, savings and money market, and time deposits; and loans, such as home equity lines of credit, residential real estate loans, consumer loans, commercial loans, commercial real estate loans, letters of credit, and lease financing. It has a 15.95 P/E ratio. It also provides debit and ATM cards, telephone access, and online banking, as well as other electronic and mobile banking services; and cash management, private banking, brokerage, trust, and investment advisory services.
Analysts await Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report earnings on March, 21. They expect $-0.90 EPS, down 83.67% or $0.41 from last year’s $-0.49 per share. After $-0.63 actual EPS reported by Aclaris Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 42.86% negative EPS growth.
Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 14 analyst reports since November 2, 2015 according to SRatingsIntel. Jefferies maintained Aclaris Therapeutics, Inc. (NASDAQ:ACRS) on Thursday, August 31 with “Buy” rating. On Friday, June 10 the stock rating was initiated by Guggenheim with “Buy”. Jefferies initiated it with “Buy” rating and $20 target in Monday, November 2 report. The rating was maintained by Cantor Fitzgerald on Tuesday, November 7 with “Buy”. Jefferies maintained it with “Buy” rating and $3600 target in Monday, June 26 report. The company was maintained on Monday, September 19 by Jefferies. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) earned “Buy” rating by Jefferies on Friday, July 28. The firm earned “Buy” rating on Friday, August 12 by Jefferies. William Blair initiated the stock with “Outperform” rating in Monday, November 2 report. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has “Buy” rating given on Wednesday, August 9 by Cantor Fitzgerald.
Since January 1, 0001, it had 0 insider buys, and 2 selling transactions for $216,429 activity.
Jcsd Capital Llc holds 4.36% of its portfolio in Old National Bancorp for 252,000 shares. Fj Capital Management Llc owns 1.24 million shares or 2.75% of their US portfolio. Moreover, Tributary Capital Management Llc has 2.06% invested in the company for 1.31 million shares. The Indiana-based Old National Bancorp In has invested 1.82% in the stock. Hourglass Capital Llc, a Texas-based fund reported 321,310 shares.